Effect of LY2189265, a long-acting glucagon-like peptide 1 analog, on metabolic outcomes and GI events in obese patients with uncontrolled type 2 diabetes mellitus (T2DM): The EGo study.
Umpierrez, G., Blevins, T., Rosenstock, J., Cheng, C., Bastyr, E., Anderson, J.Volume:
33
Year:
2009
Language:
english
Journal:
Canadian Journal of Diabetes
DOI:
10.1016/S1499-2671(09)33073-7
File:
PDF, 445 KB
english, 2009